curasan AG Receives €1.48 Million Research Grant
Kleinostheim, Germany, September 16, 2009 --(PR.com)-- curasan AG, listed on the General Standard of Deutsche Börse AG as ISIN: DE 000 549 453 8, has just received a grant of €1.48 million from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) for a bone regeneration research project scheduled to last three years. The funds are earmarked for a joint project with Ben Gurion University (BGU) of the Negev, Israel.
The Israeli working group has synthesised and patented a peptide matrix (a special protein structure) which can be used to significantly speed up the process of bone regeneration. However, the protein matrix needs to be combined with a suitable carrier material to achieve its full potential.
As a partner of BGU, curasan AG will now develop and produce a bioceramic optimised for this purpose. This new material should retain the characteristics required for the growth of bone matter that were provided by the previously available purely inorganic, absorbable materials.
“The funding that has been allocated will help us to develop a generation of products with an active mechanism”, explains Dr. Fabian Peters, Head of Research and Development of Biomaterials at curasan AG.
The aim of the research partnership is to create a special bioactive product which, when combined with organic substances, will support the body’s own healing processes and enable optimal bone regeneration. curasan AG will have the rights of sale.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
###
The Israeli working group has synthesised and patented a peptide matrix (a special protein structure) which can be used to significantly speed up the process of bone regeneration. However, the protein matrix needs to be combined with a suitable carrier material to achieve its full potential.
As a partner of BGU, curasan AG will now develop and produce a bioceramic optimised for this purpose. This new material should retain the characteristics required for the growth of bone matter that were provided by the previously available purely inorganic, absorbable materials.
“The funding that has been allocated will help us to develop a generation of products with an active mechanism”, explains Dr. Fabian Peters, Head of Research and Development of Biomaterials at curasan AG.
The aim of the research partnership is to create a special bioactive product which, when combined with organic substances, will support the body’s own healing processes and enable optimal bone regeneration. curasan AG will have the rights of sale.
Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.
###
Contact
curasan AG
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Andrea Weidner
+49 (0)6027 40 900-51
www.curasan.de
Contact
Categories